CompletedPhase 4NCT04146935
Examining the Effect of Burosumab on Muscle Function
Studying X-linked hypophosphatemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Yale University
- Principal Investigator
- Karl L Insogna, M.D., MDYale University
- Intervention
- Burosumab Injection [Crysvita](drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2019 – 2022
Study locations (1)
- Yale University School of Medicine, New Haven, Connecticut, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04146935 on ClinicalTrials.govOther trials for X-linked hypophosphatemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06525636A First-in-human Study of KK8123 in Adults With X-linked HypophosphatemiaKyowa Kirin Co., Ltd.
- ACTIVE NOT RECRUITINGNCT04946409Burden of Disease and Functional Impairment in XLHWuerzburg University Hospital
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT03748966Calcitriol Monotherapy for X-Linked HypophosphatemiaMassachusetts General Hospital
- ACTIVE NOT RECRUITINGNCT03651505X-linked Hypophosphatemia Disease Monitoring ProgramUltragenyx Pharmaceutical Inc
- ACTIVE NOT RECRUITINGNCT03745521Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian PartnersKyowa Kirin Co., Ltd.
- RECRUITINGNCT03193476Registry for Patients With X-Linked HypophosphatemiaKyowa Kirin Pharmaceutical Development Ltd